Blood contact with biomaterials triggers activation of multiple reactive mechanisms that can impair the performance of implantable medical devices and potentially cause serious adverse clinical events. This includes thrombosis and thromboembolic complications due to activation of platelets and the coagulation cascade, activation of the complement system, and inflammation. Numerous surface coatings have been developed to improve blood compatibility of biomaterials. For more than thirty years, the anticoagulant drug heparin has been employed as a covalently immobilized surface coating on a variety of medical devices. This review describes the fundamental principles of non-eluting heparin coatings, mechanisms of action, and clinical applications with focus on those technologies which have been commercialized. Because of its extensive publication history, there is emphasis on the CARMEDA ® BioActive Surface (CBAS ® Heparin Surface), a widely used commercialized technology for the covalent bonding of heparin.
5.
Mechanism and properties of covalent heparin surfaces. 
Introduction
The activation of blood defense mechanisms upon exposure to biomaterials poses a challenge to the design and performance of blood contacting medical devices. Activation of the coagulation cascade, complement system, cellular inflammatory mechanisms, and platelets are among the key adverse reactions of blood that may compromise the performance of medical devices [1, 2] . This may manifest clinically as thrombotic occlusion and embolization across a spectrum of cardiovascular medical devices, including vascular stents, grafts, and catheters, as well as cardiopulmonary bypass and oxygenation equipment, prosthetic valves, and ventricular assist devices. In some cases, for example in patients with coronary stents, mechanical heart valves, and left ventricular assist devices, chronic pharmacological inhibition with antiplatelet or anticoagulant drugs is required to protect against thrombotic complications.
Modification of medical device surfaces to improve blood compatibility has been sought to reduce device-related thrombus formation and inflammatory reactions. Surface modification technologies can be assigned into two broad categories: passivation of material surfaces and bioactive surface treatments and coatings [3] . Passive approaches are aimed at reducing the inherent thrombogenicity of the material surface through modification of surface chemistry (e.g. hydrophilicity) or material physical structure (e.g. topography). Bioactive strategies employ direct pharmacologic inhibition of the coagulation response by local drug delivery or permanent immobilization of an active agent.
A precipitating event in the modern field of blood compatible surface modifications was the serendipitous discovery of the thromboresistant properties of a heparin coated surface by Gott and colleagues in 1963 [4] . It was observed that by temporarily immobilizing the anticoagulant drug heparin at the device surface, there was marked reduction in thrombus formation on materials implanted into the vena cava. Numerous approaches to hemocompatible surface modifications have been described since [1] [2] [3] , including a number of heparin-based surface modifications [5] [6] [7] [8] .
The focus of this review is on a specific subset of commercialized non-eluting heparin coating technologies which were developed for use in the medical device industry. Of the various heparin-based technologies, the CARMEDA ® BioActive Surface (CBAS ® Heparin Surface;
Carmeda AB, Upplands Väsby, Sweden), has the most extensive publication history describing both basic biochemical mechanisms and clinical applications. Hence, this review will focus on the immobilization of the anticoagulant drug heparin with emphasis on the CBAS Heparin Surface.
Coagulation and heparin mechanism of action
Thrombus formation is the result of two interdependent mechanisms, platelets and circulating protein clotting factors. Platelets, small anuclear cells that circulate in blood in ranges from 150 × 10 6 /mL to 400 × 10 6 /mL are a critical component of hemostasis. Activation of platelets by a variety of stimuli triggers complex pathways that result in platelet aggregation and the release of potent pro-thrombotic molecules. It is well known that blood contact with artificial surfaces can elicit platelet activation by a variety of mechanisms [1] , including device related alteration in blood flow that trigger shear-related platelet activation [9] , and due to direct platelet adherence to the deposited protein layer on synthetic surfaces of the device, an event largely attributed to adsorption of fibrinogen [1, 2] . Activated platelets undergo dramatic shape changes which promote aggregation with other platelets, and release platelet and pro-coagulant agonists (such as thromboxane A2, ADP, and FVa) [10] . The phospholipids of the platelet membrane also serve as the substrate for activated clotting factors, resulting in local amplification of the coagulation cascade. Aggregation of platelets, together with explosive activation of protein clotting factors, may result in significant thrombus accumulation on the device surface, embolization of thrombus particles into the bloodstream, and may cause detectable reductions in circulating platelet count (consumption of platelets). The protein clotting factors are a set of structurally similar serine proteases that circulate in the plasma as inactive proenzymes. After vascular injury, or through the introduction of foreign materials into the circulatory system, clotting factors are triggered and undergo activation in a sequential cascade-like fashion that culminates in the formation of a fibrin clot. This cascade consists of two pathways, the intrinsic and extrinsic, each of which is triggered by different mechanisms. Tissue factor that is released due to vascular injury is the primary initiator of the extrinsic pathway [11] . The intrinsic pathway is considered the more critical pathway in biomaterial-associated thrombosis [1] . Contact activation of FXII, together with kallikrein and high molecular weight kininogen (HMWK), initiates the intrinsic pathway leading to activation of FX, and consequently conversion of prothrombin into thrombin. Thrombin converts soluble fibrinogen into insoluble fibrin, which polymerizes into an insoluble fibrous network. Clotting factor activation is typically accompanied by and promoted by platelet activation, and the resultant thrombus often contains both platelets, fibrin, and other entrapped cells (Fig. 1) . A key inhibitor of the clotting factors is the plasma serine protease inhibitor antithrombin (AT). AT binds and irreversibly inhibits the active forms of several clotting factors, including thrombin, FXa, FIXa, FXIa, and FXIIa [12] . AT-mediated inhibition of the clotting factors occurs at relatively slow rate, but is accelerated by binding to the polysaccharides heparan sulfate and heparin [13] .
Heparin is a naturally occurring linear polysaccharide that shares chemical and structural similarity to heparan sulfate, a cell surface proteoglycan that provides the natural anticoagulant surface activity of the vascular endothelium [14] . Unlike heparan sulfate, heparin is largely intracellular, within the granules of mast cells. Heparin consists primarily of two highly sulfated sugar monomers, which occur as repeating disaccharide units. The anticoagulant function of heparin is dependent on a specific sequence of five sugars (the so-called pentasaccharide sequence), which are required for efficient binding of antithrombin (AT) [15] . This sequence is only found in approximately one-third of the molecules in a commercial heparin preparation [16] [17] [18] . Binding of AT to the heparin pentasaccharide sequence causes a conformational change in the AT molecule and greatly accelerates the rate of AT-mediated inhibition of the various serine protease clotting factors by a factor of 100-1000. Importantly, heparin is not consumed in the reaction and is capable of continuously catalyzing inhibition of activated clotting factors. However, heparin in the blood stream is quickly cleared from circulation through a combination of saturable cell-based binding and non-saturable renal clearance [19] [20] [21] [22] [23] , with an average half-life of approximately 60 min for unfractionated heparin (UFH) and longer a longer half-life for low molecular weight heparins (LMWH).
Approaches to heparin immobilization for thromboresistance
Heparin-coated blood contacting medical devices have been in clinical application for more than three decades. A comprehensive description and comparison of the various commercial technologies has not been possible due to the lack of published detailed technical information on all the technologies. A partial list of commercial heparin coating technologies used in the medical device industry is provided in Table 1 .
Heparin immobilization technologies can be divided into two broad categories: eluting technologies that release heparin from the device and non-eluting technologies intended for permanent covalent immobilization of heparin to the device surface. Release-based approaches are essentially drug delivery systems that can prevent local devicerelated thrombus acutely. The release rate of heparin from the surface may be tailored through physical entrapment or ionic binding of heparin to the surface. For example, complexes of heparin with branched surfactants bearing quaternary ammonium groups can be deposited on a material surface. Blood contact causes release of the ionic complex from the surface, but the presence of the surfactant slows the rate of heparin release. Other elution-based technologies have been described in previous reviews [3, 6] .
The alternative approach intended to confer long-term surface thromboresistance is to permanently immobilize heparin to the device surface. By virtue of its strong net negative charge, low pKa due to the abundance of carboxyl and sulfo groups, and variety of chemically active functional groups, heparin can be readily immobilized by different Fig. 1 . Simplified illustration depicting activation of the coagulation cascade and platelets after contact with a material surface. Contact activation of the intrinsic pathway (via FXII activation) is triggered by the material surface. This culminates in production of thrombin and the conversion of fibrinogen into an insoluble fibrin network. Activation of the complement system, and downstream inflammatory responses, is also triggered by the intrinsic pathway. Platelet adhesion to the adsorbed protein layer (most notably fibrinogen) results in platelet activation and aggregation. Activated platelets release a number of bioactive factors (e.g. ADP, thromboxane A2, FV) that promote production of thrombin and further platelet activation. Fibrin and platelet aggregates form a thrombus on the device surface. surface conjugation chemistries [7] . Each repeating disaccharide unit offers at least one carboxyl and hydroxyl functional group which may be activated and subsequently attached to a compatible functional group on the target surface. This may be achieved by direct chemical activation of the surface to introduce complementary functional groups for immobilization of heparin, or through application of an intermediary priming matrix to which the heparin can be covalently linked. For example, the carbodiimide crosslinker EDC has been used to activate carboxyl groups along the heparin chain and then conjugate to amines incorporated into the target surface [24, 25] . Periodate oxidation of vicinal diols introduces aldehydes along the heparin chain, which may also be linked to an aminated surface by reductive amination [26] .
It is important to recognize that covalent immobilization of heparin to a material is not a guarantee that the immobilized heparin will retain its anticoagulant activity. Chemical modification or obstruction of the critical pentasaccharide sequence will reduce or eliminate the ability of heparin to bind antithrombin (AT). Thus simply achieving covalent bonding of heparin to a surface may not be sufficient to produce active thromboresistance on the surface [25] . In this context, it is relevant to recognize that the standard metric of injectable heparin potency, expressed as International Units (IU) of heparin, is not a useful means of assessing the activity of covalently bonded heparin because the reaction kinetics of bound heparin are drastically different from freely soluble heparin. For this reason it is appropriate to assess the functional activity of covalently bonded heparin by measuring the capacity of the surface to specifically uptake AT from solution [27] . An immobilization method that is durable and retains the catalytic function of heparin has the potential to confer thromboresistance to a surface for extended periods of time. These non-eluting commercialized technologies are the focus of the remainder of this review.
Commercial heparin coating technologies
While there exist numerous means to immobilize heparin to a substrate, only a relative few technologies have been successfully employed in marketed medical devices, with only a subset designed as non-eluting surfaces. Of those commercial covalent chemistries, even fewer have demonstrable evidence of surface heparin bioactivity. The amount of available published information, particularly of a technical nature, differs widely between the commercial technologies and as a result, a comprehensive comparison among them is not entirely possible. The following provides an overview of several relevant commercial noneluting heparin coatings. Biosurface. The coating consists of a hydrophilic priming layer (a modified polyethyleneimine) that enables adsorption to a variety of surfaces. Sulfonate bearing groups, PEG chains, and heparin molecules are covalently attached to the priming layer [28] . The coating is described as non-eluting, and data published by the manufacturer describes functional activity of the surface as measured by specific uptake of antithrombin (AT) [29] . This technology has been used for coating blood contacting equipment used in cardiopulmonary bypass (CPB) and on hemodialysis catheters.
Maquet BIOLINE ® Coating
The BIOLINE ® Heparin Coating was originally developed by Jostra AG and is now a technology owned by Maquet Medical (Getinge Group) and incorporated into CPB equipment and vascular grafts. The technology consists of a recombinant human albumin coating to which heparin is covalently attached [30, 31] . Detailed technical data on the coating chemistry and demonstration of surface heparin functionality by uptake of AT has not been published. In a previous review it was noted that heparin used is of high molecular weight and that the bonding approach preserves the active sequence of the heparin [5] , however no supporting information was provided.
CORLINE ® Heparin Surface (CHS™)
The CORLINE ® Heparin Surface (CHS™), developed by the Swedish company Corline Systems, AB, has been in clinic use since 1997. One major commercial application of the technology was in coronary stents. The CHS™ surface is composed of macromolecular complexes of unfractionated heparin covalently attached via a heterobifunctional crosslinker to a polyamine carrier chain [32] . The ratio of heparin to polyamine carrier is approximately 70 molecules of heparin coupled to a polyamine carrier chain. The coating process involves first preconditioning the surface with a layer of cationic polyamine and then attaching the pre-formed heparin complexes to the polyamine through ionic interactions [33] . The result is a non-leaching surface, and published reports have demonstrated detectable heparin density and AT uptake on the CHS™ surface [34, 35] . Since 2005, Corline began to expand the application of their heparin technology beyond medical devices. The technology is being investigated to treat biologic products, including cells, to improve therapies in regenerative medicine by shielding transplanted organs and cells from adverse immune reactions and reducing the inflammatory reaction to implanted collagen matrices.
Flowline BIPORE ® Heparin Surface
The Flowline BIPORE ® Heparin Surface (Jotec GmbH) is described as heparin that is bonded through covalent and ionic interactions to the substrate. This presumably involves an intermediate adhesive layer between the device surface and the heparin, but the nature of this layer has not been published. Additionally, no published data providing biochemical evidence of surface heparin functionality could be found. This heparin surface is marketed by Jotec as the Flowline BIPORE ® Heparin ePTFE vascular graft with heparin coating.
Surmodics Photolink ® Heparin Coating
Surmodics, Inc. developed a photolinking technology that serves as a platform for covalent immobilization of a variety of molecules. The process involves application of a photoreagent to the substrate followed by UV illumination under wet or dry conditions [36] . This approach has been used by Surmodics to produce a covalently immobilized heparin surface. Surmodics coatings have been used on commercial medical devices throughout the world, although specific information on which devices use the Surmodics technology are not disclosed.
Perouse POLYMAILLE ® Flow Plus Heparin
The PM ® Flow Plus Heparin Surface used by the French company Perouse Medical (acquired by the Vygon Group in 2015) is a covalent heparin surface used on ePTFE vascular grafts. Technical information on the properties of the surface, including biochemical evidence of surface heparin functionality, has not been found in the published literature.
Medtronic Hepamed™ Heparin Coating
The Hepamed™ coating developed by Medtronic was a covalent heparin coating applied to coronary stents. The coating consists of a poly(vinylsiloxane) that is first covalently attached to the stent surface. This is followed by grafting a copolymer to the poly(vinylsiloxane) followed by a third layer consisting of polyethyleneimine which is covalently attached to the copolymer. Finally, heparin is covalently coupled to the polyethyleneimine [37] . The heparin used was not depolymerized or enriched for the high affinity fraction of heparin molecules. Published data have demonstrated functional activity of the heparin surface by specific uptake of AT [37, 38] .
CARMEDA ® BioActive Surface (CBAS ® Heparin Surface)
This heparin bonding technology was developed by Carmeda AB, a wholly owned subsidiary of W.L. Gore & Associates, Inc. The technology has been used in a variety of applications including CPB equipment, hemodialysis catheters, ventricular assist devices, vascular stents, stent grafts, and vascular grafts.
The Carmeda heparin binding approach employs a single covalent bond between the reducing end of the heparin molecule and the material substrate [39] . Unfractionated heparin is first partially depolymerized by nitrous acid deamination. The process yields heparin molecules of a reduced molecular weight that contain single reactive aldehyde groups at their reducing terminus. The depolymerized heparin is subsequently covalently bonded by reductive amination to a substrate that contains amine functional groups. The amines are introduced onto the surface by application of base matrix that consists of alternating layers of the anionic polysaccharide dextran sulfate and the cationic polymer polyethyleneimine (Fig. 2) . The base matrix can be deposited on diverse types of materials (polymers, metals, glass). The end result is a permanently immobilized, stable, non-leaching coating that is a few hundred nanometers thick [40] .
The Carmeda approach of end-point attachment is predicated on the availability of relatively high affinity AT-binding preparations of heparin and the principle of preserving the ability of heparin to bind AT. Its development was spurred by a combination of events: the early and discouraging attempts to permanently bind heparin to surfaces, which often failed to preserve heparin's anticoagulant function, as well as increased understanding of heparin's mechanism of action, including the discovery of the critical pentasaccharide sequence [15] . Biochemical evidence of surface heparin functionality as measured by the specific uptake of AT has been demonstrated in multiple studies [41] [42] [43] [44] .
Mechanism and properties of covalent heparin surfaces
The following sections review in vitro studies of the end-point attached (EPA) heparin of the CBAS Heparin Surface which elucidated the basic mechanisms by which EPA-heparin acts in blood, including additional features not associated with freely soluble heparin that is administered systemically. Among the various commercialized heparin bonding technologies, the bulk of published research on basic mechanisms of action comes from studies of the CBAS Heparin Surface. The remainder of the review will focus almost exclusively on this technology. An illustrative comparison and summary of basic mechanisms of freely soluble heparin, the natural heparan sulfate of the endothelium, and EPA-heparin is shown in Fig. 3 .
Reaction kinetics
The reaction kinetics for an immobilized heparin surface are distinctly different from those of systemically administered heparin in solution. Functional non-eluting heparin surfaces would not be expected to impact clotting in the bulk, and hence have no systemic anticoagulant effects. Studies of EPA-heparin under controlled conditions in vitro have demonstrated that the inhibitory capacity of EPA-heparin toward activated clotting factors is limited by convective transport of reactants [45] and flow rate has a strong influence on the uptake of antithrombin (AT) on the surface [46] . This has implications on the relationship between surface AT uptake capacity and performance measures of the surface in blood (discussed further in Section 6).
Inhibition of activated clotting factors
Experiments conducted using recirculating in vitro blood and plasma contact models have demonstrated that materials coated with EPA-heparin reduce the formation of activated thrombin [25, 27, 47, 48] and FXa [27, 41] . In similar models it was also identified that the intrinsic clotting cascade, in which FXII activation is a key upstream trigger, is an important target of EPA-heparin [35, 49] . Contact with negatively charged surfaces by key initiators of the intrinsic pathway (high molecular weight kininogen, prekallikrein, and FXII) is required for activation [50] . In a whole human blood in vitro model examining the CBAS Heparin Surface, Gore et al. [25] also noted the absence of thrombin-antithrombin (TAT) complexes and low levels of fluid phase thrombin activation markers in blood that had recirculated over end-point attached heparin for a period of an hour. This was consistent with efficient inhibition of the clotting cascade upstream of thrombin, likely through the intrinsic pathway.
An important lesson from the studies of contact activation is that functionally inactive immobilized heparin may actually accelerate activation of the intrinsic pathway by virtue of the strong net negative charge imparted on the surface. Surfaces produced with high heparin density but low AT uptake were efficient in the uptake of FXII, but failed to promote its inhibition [35] . This raises the possibility that an inactive heparin surface that retains heparin's net negative charge may have the unintended consequence of promoting coagulation rather than preventing it.
Reduced complement activation and inflammation
The earliest clinical applications of heparin surfaces was on materials used in extracorporeal circulation, where the high surface area exposure to the polymeric materials of the circuits was known to trigger systemic inflammation due to complement activation and cellular inflammatory reactions [51] . Using in vitro models, EPA-heparin has been shown to reduce complement activation (C3 activation products, C5 activation products, terminal complement complex) [52] [53] [54] [55] [56] [57] [58] [59] as well as cellular markers of inflammation [60, 61] . The heparin-based mechanism for this effect is believed to be an indirect result of inhibition of the contact activation pathway, which can trigger activation of the complement cascade [5] as well direct inhibition of complement proteins by other serine protease inhibitors enriched on the EPA-heparin surface, such as C1-inhibitor [58] . This may also have downstream effects on cellular elements of inflammation, as inhibition of complement reduces adhesion of granulocytes to surfaces [6] . 
Reduced platelet adherence and activation
An additional feature of immobilized heparin is the reported resistance to platelet adhesion and activation. In vitro recirculatory models, in which platelets are counted before and after exposure and biomarkers of platelet activation (e.g. beta-thromboglobulin and platelet factor 4) were measured in plasma, demonstrated that EPA-heparin surfaces result in reduced platelet adhesion and activation compared with control materials [25, 48, 57, 58, [62] [63] [64] [65] [66] . Reduced platelet adhesion is attributed to reduction of fibrinogen deposition produced from a functionally active heparin surface, and the extent of reduction is correlated with the extent of AT uptake [5] . Reduced activation can be attributed to the overall considerable reduction of platelet adherence, as well as to the inhibition of platelet stimulating factors such as thrombin. It is however interesting that in its freely soluble state, heparin has mild platelet stimulating properties [67] .
Importance of preserving at binding
The ability of heparin to inhibit the clotting cascade as well as reduce platelet attachment is dependent on the specific uptake of antithrombin (AT) by the immobilized heparin [25, 41, 42, 44, 68] . Gore et al. [25] conducted a controlled evaluation comparing AT uptake and performance of various heparin surfaces using the same base matrix and material. Only end-point attached heparin conferred thromboresistance in a sensitive recirculating blood loop model using freshly collected nonanticoagulated human blood. Heparin attached by multiple covalent bonds using the common carboxylic reactive linker EDC failed to preserve thromboresistance, as did periodate oxidized heparin, which creates multiple aldehyde functionality within heparin molecules. Further evaluation of the surfaces after blood contact revealed that antithrombin uptake from blood was only detectable on the end-point attached heparin surface, further indicating that loss of heparin functionality is possible with some linking chemistries (Fig. 4) . It is important to note that these chemistries may still be viable approaches to retaining some functional activity of the heparin molecules, but the reaction conditions may need to be carefully manipulated so as to minimize interference with the AT binding site. Resistance to platelet adhesion has also been shown to be dependent on AT uptake of EPA-heparin [25, 44] as well several other heparin coatings which have demonstrated AT uptake [34, 37] . The resistance to platelet binding may thus be the indirect result of the action of heparin on the coagulation cascade, not solely due to the negative charge imparted by heparin.
In an in vitro recirculatory model, Sanchez et al. examined the relationship between the amount of AT uptake on the surface and FXII activation and plasma clotting time. Based on the process used for the CBAS Heparin Surface, the data pointed to preserved functional activity in the low single pmol of AT uptake per cm 2 surface area of material [42] .
Above the threshold value of AT uptake, no additional inhibition of FXIIa could be detected, and plasma clotting times were not further increased. This suggests that beyond a certain density of functional activity on the surface, effective thromboresistance is achieved and there may be little additional benefit gained from greater surface concentration of AT. Similar plateau-like effects were also identified when studying other heparin coatings for which AT uptake data was available [34, 37]. It was proposed that steric hindrance as result of heparin interaction with plasma proteins, including AT, may have been a contributing mechanism [42] . This may also be explained by kinetic modeling of covalently bonded heparin surfaces, which demonstrated that above a specific surface concentration of AT, reactant flux to the surface was rate limiting [45] , and hence increasingly higher levels of AT uptake would not necessarily contribute to any further biological effect.
It is important to recognize that the relationship between specific AT uptake values and certain performance attributes attributed to one type of heparin surface bonding technology may not be universal and should not be assumed to be the same for other heparin technologies. While AT uptake is a key measure of surface functionality, heparin is not the only entity exposed on a heparin coated surface. Other chemical groups, surface charge, surface coverage, and specific flow dynamics associated with a specific coating technology may also influence the reactivity of the surface with blood components. The level of AT binding required to mitigate against these effects will thus likely vary between technologies.
Protein binding to heparin surfaces
Heparin is known to bind to many proteins, including protease inhibitors other than antithrombin (AT), enzymes, growth factors, chemokines, and a variety of pathogen proteins [69] . Heparin-protein interactions occur through non-specific ionic interactions (because of heparin's strong anionic character) [70] and through sequence-specific high affinity interactions (as with AT) [71] . Indeed because of the recognized relatively high affinity binding (K D b 10 −6 M) of certain types of proteins, heparin has been used as a vehicle for drug delivery, most notably of growth factors [8] .
While it is recognized that selective AT uptake is required for a functionally active thromboresistant heparin surface, it has also been proposed that other protein interactions may contribute to the observed hemocompatibility of functional surfaces. Weber et al. [58] proposed that binding (or notable absence) of certain plasma proteins may also contribute to the mechanism of action, most notably the absence or reduced binding of platelet adhesive proteins such as fibrinogen and complement protein C3 [57] . Previous studies have demonstrated differences in the uptake of these proteins between various heparin technologies, with lowest binding of fibrinogen and C3 on the CBAS Heparin Surface [57] . In a study of EPA-heparin, Gore et al. [25] observed that AT constituted 40% of the total protein uptake from blood after acute contact, but in separate studies also noted the presence of other protease inhibitors such as heparin cofactor II and the absence of fibrinogen, cell adhesive proteins such as fibronectin and vitronectin, and complement proteins [72] . The net result of these acute protein interactions may contribute to the long-term remodeling that takes place chronically on blood contacting surfaces coated with the CBAS Heparin Surface. In the same model described by Begovac et al. [43] , which demonstrated improved patency at 6 months and sustained AT uptake on vascular grafts for at least 3 months in vivo, there was significantly reduced protein deposition compared to uncoated controls [73] (Fig. 5 ).
Product considerations
The ability to preserve antithrombin (AT) uptake under physiological conditions is a key attribute required for creating a functionally active heparin coated surface. While robust in vitro data in model Fig. 4 . Western blot analysis for antithrombin (AT) and thrombin in protein recovered from different heparin bonded surfaces after acute blood contact with whole human non-anticoagulated blood. A) AT observed as a band of~54 kDa was most intense on the end-point attached heparin surface (EPA-Heparin). Alternative multi-point covalent bonding schemes using periodate (PO-heparin) and the crosslinker EDC (EDC-Heparin) yielded less AT binding not recognizably different from end-point attached heparin with low affinity for AT (LA EPA-Heparin). The higher molecular weight band was determined to be thrombin-antithrombin complex (TAT). B) Western blot for thrombin showed active free thrombin~35 kDa band on all surfaces except end-point attached heparin. The higher molecular weight band at~80 kDa was identified as TAT. From S. Gore, J. Andersson, R. Biran, C. Underwood, J. Riesenfeld, Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption, J Biomed Mater Res B Appl Biomater, 102 (2014) 1822 [25] . Copyright 2014 by Wiley Periodicals, Inc. Reprinted with permission. Fig. 5 . Analysis of total protein mass recovered from explants of ePTFE vascular grafts containing the CBAS Heparin Surface and control uncoated ePTFE vascular after various implant durations in a canine bypass model. Significantly less protein mass was deposited on vascular grafts coated with the CBAS Heparin Surface compared with controls. Deposition of protein on the uncoated grafts was highly variable. Data from Fisher et al. [73] . systems are important, there are other important considerations for development of a heparin coating to be used as part of an implantable device in the clinic. Many of these requirements are part of international and regional standards required by regulatory bodies. Specific considerations for a heparin coating include demonstration that the coating is sufficiently durable to survive downstream product processing and shelf life, including mechanical manipulation, sterilization, and packaging. Here multiple mechanisms may be involved in the deterioration of heparin activity: chemical degradation, chemical modification or reduced availability of the active site, and mechanical damage to the coating (i.e. loss of integrity). Hence it is not only important to demonstrate AT uptake initially, but to ensure that sufficient levels are maintained throughout processing and shelf life of the product. In addition, functionally active heparin must be sufficiently uniform across the surface area of the material so that the thromboresistant performance of the surface is not compromised by uncoated regions or by exposure of any other component of the surface. For this reason, biochemical activity must also be verified by performance testing in blood and other appropriate preclinical models.
Because it is not consumed in the AT-mediated inhibition of clotting factors, immobilized functionally active heparin should in theory render a surface thromboresistant over extended periods of time if the heparin is not otherwise degraded. This catalytic activity of heparin is the key feature of its attractiveness for permanent covalent immobilization. In a series of chronic implant studies, it was shown that AT-uptake was retained on the CBAS Heparin Surface of ePTFE vascular grafts after 3 months in vivo [43] and after at least 1 year in ventricular assist devices (VADs) [74, 75] . Durability of the surface is further supported by anecdotal reports of retained functionally active AT uptake by CBAS Heparin Surfaces in explants of the GORE ® PROPATEN ® Vascular Graft after implant periods of up to 8 years [76] . Published data on longterm in vivo durability of other covalent heparin coating technologies could not be found.
Performance of CBAS Heparin Surfaces in vivo
The CBAS Heparin Surface has been successfully used on a number of blood contacting medical devices and substrates for both acute and chronic settings. This includes hemodialysis catheters, peripheral and coronary vascular stents, stent grafts, and ventricular assist devices.
Extracorporeal circulation equipment
Blood exposure to a high surface area of polymeric materials of extracorporeal circuits is known to trigger systemic inflammation due in part to complement activation [51] . In addition, longer term circulation on extracorporeal membrane oxygenation (ECMO) is also complicated by bleeding complications due to chronic pharmacologic anticoagulation required to prevent circuit thrombosis. Application of the CBAS Heparin Surface to blood contacting equipment of extracorporeal circuits resulted in significant reductions in clotting factor, complement activation, cellular inflammatory markers, and platelet activation in animal models [59, 77, 78] and in human clinical studies [54, [79] [80] [81] [82] . In addition, it was demonstrated that systemic heparin dosing could be reduced or eliminated without adverse coagulation or inflammatory responses [83] [84] [85] and resulted in a lower rate of blood loss requiring transfusion, shorter hospitalization periods, and improvement in treatment cost [86] .
Despite a wealth of strong in vitro data demonstrating reductions in adverse blood reaction to various heparin coated circuits, widespread and consistent clinical benefit in the hands of different research groups has not been as clear, and there is a lack of studies that directly compare the performance attributes of different heparin coated circuits [87] . However, meta-analyses of numerous studies, including both heparin eluting and covalently bonded heparin circuits have demonstrated improved outcomes with heparin-coated circuits compared to uncoated circuits [88] . In a more contemporary review of the subject, there continue to be improved outcomes associated with heparin coated surfaces [89] . In a meta-analysis that compared the CBAS Heparin Surface with the an ionically bonded heparin surface (DURAFLO II ® ) and uncoated circuits, there was a clear benefit associated with the heparin coated circuits, and a greater magnitude and significance associated with the CBAS Heparin coated circuits [90] .
Ventricular assist devices
Ventricular assist devices (VADs) are used to bridge patients for heart transplantation. Systemic treatment with anticoagulants is required to mitigate against clot formation in the equipment. However, serious thromboembolic events still occur. Application of the CBAS Heparin Surface to VADs developed by Berlin Heart GmbH reduced clot deposition within the pump and lengthened the duration that patients could be effectively maintained on the VAD [91] .
Coronary stents
Device-related thrombosis is a potentially life threatening adverse outcome associated with the use of coronary stents. What were initially high acute thrombosis (SAT) rates with the first generations of metallic stents was reduced due to improvements in stent placement techniques, product design enhancements, and effective dual antiplatelet therapy [92] [93] [94] [95] . Even with these improvements, acute thrombosis rates were still between 1% and 3% [96] . Before the full emergence of drug eluting coronary stents (DES), the CBAS Heparin Surface and other heparin technologies were evaluated as surface treatments for metallic coronary stents. Studies on a number of different stents indicated coating with the CBAS Heparin surface resulted in improvement in thrombosis, reduced platelet deposition, and reduced intimal hyperplasia in animal models [44, [97] [98] [99] [100] [101] [102] . In a large single center retrospective study, significant reductions in thrombosis rates were observed for the stents coated with the CBAS Heparin Surface compared with bare metal stents [96] , however registry data from a larger patient population did not demonstrate significant differences between coronary stents coated with the CBAS Heparin Surface and uncoated bare metal stents [103] . This was due in part to difficulty in effectively powering studies because of the overall low rates of acute thrombosis. Two other covalent heparin coatings with established surface heparin activity were used on coronary stents and had a similar clinical experience [38, [104] [105] [106] [107] . 
Vascular grafts
Synthetic vascular grafts have a long history of use as "off the shelf" alternatives to autologous vein for peripheral bypass of diseased vessels. Synthetic grafts composed of ePTFE provided favorable outcomes in peripheral bypass, but nevertheless produced lower patency rates than autologous vein. As a result ePTFE grafts are considered a suitable prosthetic when autologous saphenous vein is not available. As diameter decreases below 6 mm, patency of synthetic vascular grafts is generally viewed as suboptimal, particularly in bypass applications below the knee. Primary modes of failure include occlusion of the graft lumen by thrombus or intimal hyperplasia, both of which contribute to reduced patency. Early studies of ePTFE vascular grafts coated with the CBAS Heparin Surface demonstrated dramatic reduction in occlusive thrombus (Fig. 6 ) and significant improvement in patency compared with uncoated control grafts for at least 6 months in vivo [43, 108] . Animal models also demonstrated that the CBAS Heparin Surface reduced platelet attachment and peri-anastomotic intimal hyperplasia on ePTFE vascular grafts [109, 110] . Extensive clinical evaluation of ePTFE vascular grafts coated with the CBAS Heparin Surface have shown improved patency relative to uncoated grafts [40] . There are risks associated with the use of heparin, including the rare but potentially life threatening complication of Heparin Induced Thrombocytopenia (HIT). HIT is a transient, antibody-mediated hypercoagulability state that can be life-threatening with an incidence rate of b1-5% in surgical patients [113] . It is caused by antibodies that form in response to complexes of heparin and platelet factor 4 (PF4). It is observed clinically as a severe decline in circulating platelets sometimes accompanied by thrombosis that follows a well described timeline [114] [115] [116] , with typical onset of thrombocytopenia occurring between 5 and 10 days following heparin exposure. The immunological features of HIT are somewhat unique. Anti-PF4/heparin antibodies persist only briefly, disappearing from circulation between 50 and 85 days. The immune response is also not anamnestic. If circulating antibodies have disappeared, history of HIT does not predict formation of antibodies upon re-exposure to heparin [115] . However if antibodies are already in circulation, as a result of recent heparin administration, re-exposure to heparin accelerates thrombocytopenia [115] .
For devices incorporating heparin, there is a paucity of published studies on whether covalently immobilized heparin may cause or contribute to the condition. Available data have not demonstrated a causal relationship between covalently immobilized heparin and either the initial immunizing event or exacerbation of ongoing HIT. Definitive conclusions are difficult to draw because interpretation is confounded by the near ubiquitous use of relatively large doses of injectable heparin prior to, during, and after implantation of heparin coated devices [117] .
Serology studies on the occurrence of anti-PF4/heparin antibodies over time in patients with devices coated with the CBAS Heparin Surface have provided insight as to whether the presence of the CBAS Heparin Surface affects the rate of anti-PF4/heparin antibody seroconversion. Two separate studies examining a total of 87 patients who received ventricular assist devices (VAD) showed no difference in the occurrence of anti-PF4/heparin antibodies in groups who received the devices with the CBAS Heparin Surface compared with those who received uncoated devices [118, 119] . Furthermore, in both the CBAS Heparin Surface group and the uncoated group, approximately 66% of the patients who were initially positive for anti-PF4/heparin antibodies became seronegative after systemic injectable heparin was discontinued [118] .
Several case reports on the GORE ® PROPATEN ® Vascular Graft, which contains the CBAS Heparin Surface, suggested that the presence of the covalently bonded heparin on the graft contributed to HIT [120] [121] [122] . These cases involved the use of systemic heparin perioperatively and/or postoperatively. In all but one of the cases, the timing of events and assay results were suggestive of delayed-onset HIT [117] . Delayed onset HIT is characterized by the presence of antibodies that are capable of heparin-independent platelet activation [123] .It is frequently observed that patients with this condition experience declining platelet count and ongoing hypercoagulability even after heparin is discontinued. In one reported case of HIT associated with the GORE ® PROPATEN ® Vascular Graft, a follow-up investigation of the patient's serum confirmed a serological profile consistent with delayed onset HIT, again calling into question the role of the graft in contributing to the event [117] . Numerous cases of delayed onset HIT have been reported in patients for which heparin has been discontinued and no heparin coated devices have been implanted. Analysis of the suspected delayed onset HIT cases associated with the presence of devices coated with the CBAS Heparin Surface called into question whether the devices contributed to the condition or their presence was simply coincidental [117] .
Conclusions
Decades of investigation and clinical experience with covalently bonded heparin coatings have demonstrated the basic mechanisms and clinical benefits of this technology in a number medical device applications. Because it is not a drug releasing technology, the mechanisms of a permanently bonded heparin surface are different from those of device-based drug releasing systems, and it follows that design considerations also differ. Numerous studies have demonstrated that retaining the anticoagulant activity of heparin, by preserving the ability to bind antithrombin and catalyze the inhibition of clotting factors, is central to the design of a functional heparin surface. Not all approaches to heparin bonding achieve the prerequisite of preserving antithrombin binding, and it is thus important to recognize that not all heparin coatings are equivalent. Although there continue to be development and advances in new and novel coating technologies for blood-contacting medical devices, functionally active non-eluting heparin bonding remains a viable and effective approach for enhancing the hemocompatibility of medical devices. 
